Evidence map›Paper›PMID 35387611›Full record

Trial reportBMC public health2022

Addressing the COVID-19 pandemic challenges for operational adaptations of a cluster randomized controlled trial on dengue vector control in Malaysia.

Mitra Saadatian-Elahi, Neal Alexander, Tim Möhlmann, Farah Diana Ariffin, Frederic Schmitt, Jason H Richardson, Muriel Rabilloud, Nurulhusna Ab Hamid

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Acceptability of Integrated Vector Management ofTropical medicine and infectious disease · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 5 countries.

Mitra Saadatian-ElahiService Hygiène, Epidémiologie, Infectiovigilance Et Prévention, Centre Hospitalier Edouard Herriot, Hospices Civils de Lyon, Lyon, France. mitra.elahi@chu-lyon.fr.ORCID 0000-0003-1265-8806
Neal AlexanderMRC International Statistics and Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel St, London, WC1E 7HT, UK.
Tim MöhlmannIn2Care B.V, Marijkeweg 22, 6709PG, Wageningen, the Netherlands.
Farah Diana AriffinMedical Entomology Unit, WHO Collaborating Centre for Vectors, Institute for Medical Research, Ministry of Health Malaysia, National Institutes of Health, Block C, Jalan Setia Murni U13/52, Seksyen U13, Setia Alam, 40170, Shah Alam, Malaysia.
Frederic SchmittBayer S.A.S, Environnemental Science, Crop Science Division, 16 rue Jean Marie Leclair, CS 90106 , 69266, Lyon Cedex 09, France.
Jason H RichardsonInnovative Vector Control Consortium, Pembroke PlaceLiverpool, L3 5QA, UK.
Muriel RabilloudUniversité de Lyon, F-69000, Lyon, France; Université Lyon 1, F-69100, Villeurbanne, France; Hospices Civils de Lyon, Pôle Santé Publique, Service de Biostatistique Et Bioinformatique, F-69003, Lyon, France; CNRS, UMR 5558, Laboratoire de Biométrie Et Biologie Évolutive, Équipe Biostatistique-Santé, F-69100, Villeurbanne, France.
Nurulhusna Ab HamidMedical Entomology Unit, WHO Collaborating Centre for Vectors, Institute for Medical Research, Ministry of Health Malaysia, National Institutes of Health, Block C, Jalan Setia Murni U13/52, Seksyen U13, Setia Alam, 40170, Shah Alam, Malaysia.
Ministry of Health · MYUniversité Claude Bernard Lyon 1 · FRBayer (France) · FRHumanTotalCare (Netherlands) · NLInnovative Vector Control Consortium · GBLondon School of Hygiene & Tropical Medicine · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe COVID-19 pandemic placed an unprecedented overload on healthcare system globally. With all medical resources being dedicated to contain the spread of the disease, the pandemic may have impacted the burden of other infectious diseases such as dengue, particularly in countries endemic for dengue fever. Indeed, the co-occurrence of COVID-19 made dengue diagnosis challenging because of some shared clinical manifestations between the two pathogens. Furthermore, the sudden emergence and novelty of this global public health crisis has forced the suspension or slow-down of several research trials due to the lack of sufficient knowledge on how to handle the continuity of research trials during the pandemic. We report on challenges we have faced during the COVID-19 pandemic and measures that were implemented to continue the iDEM project (intervention for Dengue Epidemiology in Malaysia).

methodsThis randomized controlled trial aims to assess the effectiveness of Integrated Vector Management (IVM) on the incidence of dengue in urban Malaysia by combining: targeted outdoor residual spraying (TORS), deployment of auto-dissemination devices (ADDs), and active community engagement (CE). Our operational activities started on February 10, 2020, a few weeks before the implementation of non-pharmaceutical interventions to contain the spread of COVID-19 in Malaysia.

resultsThe three main issues affecting the continuity of the trial were: ensuring the safety of field workers during the interventions; ensuring the planned turnover of TORS application and ADD deployment and services; and maintaining the CE activities as far as possible.

conclusionsEven though the pandemic has created monumental challenges, we ensured the safety of field workers by providing complete personal protective equipment and regular COVID-19 testing. Albeit with delay, we maintained the planned interval time between TORS application and ADDs services by overlapping the intervention cycles instead of having them in a sequential scheme. CE activities continued remotely through several channels (e.g., phone calls and text messages). Sustained efforts of the management team, significant involvement of the Malaysian Ministry of Health and a quick and smart adaptation of the trial organisation according to the pandemic situation were the main factors that allowed the successful continuation of our research.

trial registrationTrial registration number: ISRCTN-81915073 . Date of registration: 17/04/2020, 'Retrospectively registered'.

Indexed as

COVID-19DengueCOVID-19 TestingHumansMalaysiaPandemicsCOVID-19DengueMalaysiaRandomized controlled trialVector control

Identifiers

PMID35387611
PMCPMC8985393
OpenAlexW4226073243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.